RIGI and infection: In fact, the therapeutic treatment with RIG-I agonists prevented infection with SARS-CoV-2 in an IFN-dependent manner (Mao et al., 2022) and the prophylactic and therapeutic treatment with another RIG-I agonist improved survival after SARS-CoV-2 infection by preventing viral replication and inflammation (Marx et al., 2022).